Trial
NCT01495247
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Inoperable Locally Advanced Breast Cancer
Intervention
BEZ235
Why stopped
Study did not meet Phase Ib primary objective to establish the maximum tolerated dose/recommended dose for Phase II
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-08